The purpose of vaccinating children was originally to stop dangerous diseases that spread easily and quickly in a school room ...

Gazyva is also being studied in children and adolescents with lupus nephritis and patients with membranous nephropathy, ...

The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus ...

Today, a brief rundown of news from GSK and Roivant, as well as updates from Zealand Pharma, Eli Lilly and Xencor that you may have missed. GSK will not advance an experimental vaccine for the herpes ...

Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in ...

UCB and Biogen revealed that their Phase 3 study testing dapirolizumab pegol in people with systemic lupus erythematosus met ...

A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...

while GSK's Benlysta, which first gained approval in 2011, brought in 1.35 billion euros ($1.50 billion) last year. Several other drugmakers are also developing experimental lupus drugs.

As usual, a second trial will be needed before UCB and Biogen can file dapirolizumab pegol with regulators. It will be called ...